“In science, nobody can say no to any possibility,” says Sanjay Singh, founder CEO of Gennova Biopharmaceuticals Ltd during an interview with Scrip. It’s perhaps this belief that led him and his team to develop India’s first, and the world’s third mRNA vaccine.
Before he set up Gennova in 2006, Singh’s drive to develop treatments for diseases like malaria and his tenure at the International Center for Genetic Engineering and Biotechnology led to a stint at The National Institutes of Health (NIH) in the US
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?